Importance of Long-Acting Injectable Antipsychotic Preparation, Administration, and Injection Site Tolerability: A Focus on Paliperidone Palmitate Once-Every-6-Months Formulation
Table 1
Baseline demographics and disease characteristics in the double-blind intention-to-treat analysis set [16].
Characteristic
PP6M, n = 478
PP3M, n = 224
Mean age (SD), years
41.2 (11.77)
40.0 (10.98)
Sex, n (%)
Male
326 (68.2)
154 (68.8)
Race, n (%)
White
353 (73.8)
168 (75.0)
Asian
66 (13.8)
30 (13.4)
Black and/or African American
49 (10.3)
23 (10.3)
Othera
6 (1.3)
2 (0.9)
Ethnicity, n (%)
Not Hispanic or Latino
397 (83.1)
197 (87.9)
Hispanic or Latino
75 (15.7)
25 (11.2)
Unknown
6 (1.3)
2 (0.9)
Mean baseline weight (SD), kgb
81.9 (16.86)
80.8 (17.01)
Mean baseline BMI (SD), kg/m2b
27.9 (4.96)
27.5 (4.96)
Mean age at first diagnosis of schizophrenia (SD), years
27.7 (9.01)
27.5 (9.05)
Note. BMI, body mass index; PP3M, paliperidone palmitate once-every-3-months; PP6M, paliperidone palmitate once-every-6-months. aIncludes patients who self-identified as Native Hawaiian or other Pacific Islander and as multiple races. bBased on open-label data.